Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating
results for the second quarter of 2012. Total revenue for the
quarter was $66.4 million, including approximately $1.4 million in
revenue from eBioscience following the close of Affymetrix’s
acquisition of the company on June 25. This compares to total
revenue of $64.7 million for the same period of 2011.
The Company reported net income of approximately $30.9 million,
or $0.43 per diluted share, in the second quarter of 2012 compared
to a net loss of $3.7 million, or $0.05 per diluted share, in
the same period of 2011. The second quarter of 2012 included the
following one-time items: (1) an income tax benefit related to the
eBioscience acquisition of $44.7 million, (2) acquisition-related
non-recurring costs of $4.7 million, (3) a stock compensation
charge of $8.3 million related to the acceleration of stock options
held under eBioscience equity incentive plans, and (4) the recovery
of a $2.2 million note that had been provided for in full.
Excluding these one-time items and recurring amortization of
acquired intangible assets and release of step-up in inventory fair
value, the Company would have reported a net loss of $1.2 million,
or $0.02 per diluted share. This compares to a net loss of $2.1
million, or $0.03 per diluted share, in the same period of 2011
excluding recurring amortization of acquired intangible assets.
Total revenue for the second quarter of 2012 was $66.4 million,
comprised of product revenue of $58.5 million and service and other
revenue of $7.9 million. Product revenue included consumable
revenue of $53.3 million, instrument revenue of $3.8 million, and
revenue from eBioscience of $1.4 million. This compares to total
revenue of $64.7 million in the second quarter of 2011, comprised
of product revenue of $58.1 million and service and other
revenue of $6.6 million. Product revenue included consumable
revenue of $54.3 million and instrument revenue of
$3.8 million.
For the second quarter of 2012, cost of product sales, including
eBioscience, was $24.4 million, as compared to $22.4 million in the
same period of 2011. Product gross margin was 58%, as compared to
62% in the same period of 2011. Cost of services and other was $3.3
million compared to $3.4 million in the same period of 2011.
For the second quarter of 2012, operating expenses were $54.1
million, including acquisition-related non-recurring costs of $4.7
million and a stock compensation charge of $8.3 million related to
the acceleration of stock options held under eBioscience equity
incentive plans. This compared to operating expenses of $42.0
million in the same period of 2011.
“During the second quarter we completed the acquisition of
eBioscience which allows us to access significant new markets to
drive future growth and profitability,” said Frank Witney,
president and chief executive officer. “In addition, we generated
double-digit growth in a number of our key business areas as we
continue on our path to return to overall growth. We exited the
quarter with gross cash-on-hand of about $38 million and we expect
to generate cash in the second half of the year after interest and
principal payments.”
Second quarter
highlights:
- On June 25th, the Company announced
that it had completed the acquisition of eBioscience, a
privately-held company with an industry-leading position in flow
cytometry and immunoassay reagents for immunology and oncology
research and diagnostics. The acquisition enhances Affymetrix’s
product portfolio and expands its addressable markets by more than
$2.5 billion per year. Through the acquisition of eBioscience, the
Company can now offer a blue-chip portfolio of cell-based assays
that diversifies the business and opens up important new avenues
for growth. With eBioscience’s portfolio of profitable and growing
reagents, the combined Company intends to introduce novel molecular
solutions to enter sizable new markets.
- Signed a worldwide distribution
agreement for ScreenCell’s isolation devices and dilution buffers,
designed for the collection of Circulating Tumor Cells (CTCs) in
peripheral blood. The Company expects this platform will help to
improve disease detection, enabling researchers in translational
sciences to further examine the impact on treatment, management and
outcome in cancer.
- Announced a world-wide collaboration
with Leica Microsystems that automates Affymetrix’s QuantiGene
ViewRNA ISH Tissue Assay on the Leica BOND RX staining platform for
research applications. This partnership provides researchers with a
powerful automated everyday solution for drug-discovery,
translational research, and the development of new companion
diagnostic tests for personalized medicine by significantly
reducing assay time for single-copy RNA in situ hybridization (ISH)
analysis. The highly-sensitive QuantiGene® ViewRNA ISH Tissue Assay
assists drug discovery and translation research by enabling
researchers to measure RNA expression directly in a tissue section
at single-copy sensitivity. Over 1,000 standard probes are already
available and it only takes a few days to produce a customized
probe for a new gene target. The Leica BOND RX system
automates the staining process bringing all the benefits of
consistency, reduced labor, and speed. This means researchers can
now have access to same-day assay completion and, with a
standardized staining protocol, rapid set-up for any probe.
- Announced a research collaboration and
licensing agreement with Massachusetts General Hospital to
co-develop new cancer biomarker tests using Affymetrix’s
QuantiGene® ViewRNA Assay platform, an in situ hybridization assay
capable of single transcript in single-cell detection. As part of
this agreement, Affymetrix has the rights to commercialize the new
biomarker tests as an outcome of this collaboration.
Affymetrix's management team will host a conference call on July
31, 2012 at 2:00 p.m. PT to review its operating results for the
second quarter of 2012. A live webcast can be accessed by visiting
the Investor Relations section of the Company’s website at
www.affymetrix.com. In addition, investors and other interested
parties can listen by dialing domestic: (877) 407-8291,
international: (201) 689-8345.
A replay of this call will be available from 5:00 p.m. PT on
July 31, 2012 until 8:00 p.m. PT on August 8, 2012 at the following
numbers: domestic: (877) 660-6853, international: (201) 612-7415.
Please enter account #376 and conference passcode 397718 to access
the replay. An archived webcast of the conference call will be
available under the Investor Relations section of the Company's
website.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
2,200 systems have been shipped around the world and more than
25,000 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, California,
and has manufacturing facilities in Cleveland, Ohio, and Singapore.
eBioscience is headquartered in San Diego, California and has
manufacturing facilities in San Diego and Vienna, Austria.
Including eBioscience, the Company has about 1,200 employees
worldwide and maintains sales and distribution operations across
Europe, Asia and Latin America.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix's "expectations," "beliefs," "hopes,"
"intentions," "strategies" or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected, including,
but not limited to: Affymetrix's ability to timely and successfully
integrate and realize the anticipated strategic benefits and costs
savings or other synergies of the acquisition of eBioscience in a
cost-effective manner while minimizing the disruption to its
business; risks that eBioscience’s future performance may not be
consistent with its historical performance; risks relating to
Affymetrix's ability to make scheduled payments of the principal
of, to pay interest on or to refinance its indebtedness; risks
relating to Affymetrix's ability to successfully develop and
commercialize new products, including its ability to successfully
develop and commercialize novel molecular solutions based on
eBioscience’s portfolio of reagents; risks relating to past and
future acquisitions, including the ability of Affymetrix to
successfully integrate such acquisitions into its existing
business; risks of Affymetrix's ability to achieve and sustain
higher levels of revenue, higher gross margins and reduced
operating expenses; risks relating to Affymetrix’s ability to
generate cash in the second half of 2012 after interest and
principal payments; uncertainties relating to technological
approaches; risks associated with manufacturing and product
development; personnel retention; uncertainties relating to cost
and pricing of Affymetrix products; dependence on collaborative
partners; uncertainties relating to sole-source suppliers;
uncertainties relating to FDA and other regulatory approvals;
competition; risks relating to intellectual property of others and
the uncertainties of patent protection and litigation. These and
other risk factors are discussed in Affymetrix's Annual Report on
Form 10-K for the year ended December 31, 2011, and other SEC
reports. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
In addition to providing financial measures based on generally
accepted accounting principles in the United States (GAAP),
Affymetrix has disclosed in this press release its net loss and net
loss per share for the second quarter of 2012 excluding specified
one-time items related to its acquisition of eBioscience, recurring
amortization of acquired intangible assets and release of step-up
in the inventory fair value, as well as its net loss and loss per
share for the second quarter of 2011 excluding amortization of
acquired intangible assets. Affymetrix has determined to disclose
this financial information to investors because it believes it will
be useful, as a supplement to GAAP measures, in comparing
Affymetrix’ operating performance in the second quarter of 2012 to
the prior-year period. These non-GAAP financial measures should not
be considered in isolation from, or as a substitute for, financial
information prepared in accordance with GAAP. Affymetrix has
provided a reconciliation of these financial measures to net income
(loss).
PLEASE NOTE:
Affymetrix, the Affymetrix logo, GeneChip, and all other
trademarks are the property of Affymetrix, Inc.
AFFYMETRIX, INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(IN THOUSANDS)
June 30, December 31,
2012 2011 (Unaudited) (See Note
1)
ASSETS: Current assets: Cash and cash equivalents $
26,732 $ 201,937 Restricted cash 682 692 Available-for-sale
securities—short-term portion 2,239 7,937 Accounts receivable, net
53,360 44,021 Inventories 91,966 42,851 Deferred tax
assets—short-term portion 342 364 Property and equipment, net—held
for sale 9,000 9,000 Prepaid expenses and other current assets
14,522 7,785 Total current assets
198,843 314,587 Available-for-sale securities—long-term portion
7,912 54,501 Property and equipment, net 34,142 30,583 Goodwill
140,325 - Intangible assets, net 184,857 29,525 Deferred tax
assets—long-term portion 5,806 450 Other long-term assets
17,044 8,369 Total assets $ 588,929 $
438,015
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Current liabilities: Accounts payable and accrued liabilities $
54,658 $ 44,774 Term loan—short-term portion 6,375 - Deferred
revenue—short-term portion 10,806 9,852
Total current liabilities 71,839 54,626 Deferred revenue—long-term
portion 3,727 3,959 Convertible notes 105,000 95,469 Term
loan—long-term portion 78,625 - Other long-term liabilities 23,703
9,127 Stockholders’ equity: Common stock 706 704 Additional paid-in
capital 755,000 750,332 Accumulated other comprehensive income
2,349 2,492 Accumulated deficit (452,020 ) (478,694 )
Total stockholders’ equity 306,035 274,834
Total liabilities and stockholders’ equity $ 588,929
$ 438,015
Note 1: The condensed consolidated balance sheet at
December 31, 2011 has been derived from the audited consolidated
financial statements at that date included in the Company’s Annual
Report on Form 10-K for the fiscal year ended December 31,
2011.
AFFYMETRIX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE
AMOUNTS)
(UNAUDITED)
Three Months Ended Six Months
Ended June 30, June 30, 2012
2011 2012
2011 REVENUE: Product sales $ 58,505 $ 58,144
$ 116,996 $ 125,607 Services and other 7,898
6,515 14,654 12,776 Total
revenue 66,403 64,659 131,650
138,383
COSTS AND EXPENSES: Cost of
product sales 24,363 22,367 47,928 46,266 Cost of services and
other 3,319 3,426 7,098 6,626 Research and development 13,588
15,298 26,919 31,566 Selling, general and administrative
40,526 26,675 68,450
53,887 Total costs and expenses 81,796
67,766 150,395 138,345 (Loss)
income from operations (15,393 ) (3,107 ) (18,745 ) 38 Interest
income and other, net 2,276 499 2,302 (1,395 ) Interest expense
218 937 1,198
1,875 Loss before income taxes (13,335 ) (3,545 ) (17,641 )
(3,232 ) Income tax (benefit) provision (44,226 ) 127
(44,315 ) 401 Net income (loss) $
30,891 $ (3,672 ) $ 26,674 $ (3,633 ) Basic
net income (loss) per common share $ 0.44 $ (0.05 ) $ 0.38
$ (0.05 ) Diluted net income (loss) per common share $ 0.43
$ (0.05 ) $ 0.38 $ (0.05 )
Shares used in computing basic net income
(loss) per common share
70,161
69,504
70,069
70,700
Shares used in computing diluted net
income (loss) per common share
71,918
69,504
72,263
70,700
AFFYMETRIX, INC.
ITEMIZED RECONCILIATION BETWEEN GAAP
AND NON-GAAP NET INCOME (LOSS)
(IN THOUSANDS)
(UNAUDITED)
Three Months Ended Six Months Ended
June 30, June 30, 2012
2011 2012
2011 GAAP net income (loss) - diluted $ 30,891 $
(3,672 ) $ 26,674 $ (3,633 ) Amortization of inventory fair value
adjustment 319 - 319 - Amortization of acquired intangible assets
1,543 1,544 2,903 3,088 Acquisition-related transaction costs 4,710
- 5,767 - Share-based compensation charge related to acquisition
8,265 - 8,265 - Recovery of notes receivable previously reserved
for (2,215 ) - (2,215 ) - Impairment of non-marketable investments
- - - 1,157 Income tax benefit related to acquisition
(44,704 ) - (44,704 ) - Non-GAAP
net income (loss) - diluted (1,191 ) (2,128 )
(2,991 ) 612
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024